PMA EXPANDING PUBLIC COMMUNICATIONS EFFORT
PMA EXPANDING PUBLIC COMMUNICATIONS EFFORT with a program designed to extend its message to audiences outside the Washington, D.C. area. The Pharmaceutical Manufacturers Association said its board "authorized an expansion of its communications program to emphasize the value of the industry's contributions to health and health care cost containment through research." The association will continue its industry information campaign through advertising space in D.C.-area publications, such as the Washington Post and the Congressional Quarterly. However, PMA additionally has contracted with the Baltimore-based public relations consultant Eisner & Associates to spread the PMA gospel outside the capital area. Under a contract said to be in the $5-$7 mil. range, PMA will place print ads in publications designed to target volunteer health groups, such as the American Cancer Society, and health care opinion leaders representing the elderly and other patient populations. Eisner President Steve Eisner is a former project associate with APCO, the Arnold & Porter Consulting group based in D.C. Although the contract is for one year, the PMA board is said to have committed to a multiple-year communications program for the industry. In a Dec. 9 press announcement, PMA President Gerald Mossinghoff said "most Americans do not know" much "important factual information" about the drug industry. For example, he said, they do not know "that the industry will invest over $9 bil. this year in the search for new medicines or that the vast majority of pharmaceutical breakthroughs come from the research- based industry."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth